RecruitingNot ApplicableNCT07285564
Performance of 18F-FDG Micro-PET-CT in the Assessment of Surgical Margins in Head and Neck Cancer
Sponsor
Centre Henri Becquerel
Enrollment
10 participants
Start Date
Nov 7, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate the diagnostic performance of 18F-FDG micro-PET-CT in malignant Head and neck cancer compared to definitive histological analysis (gold standard).
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This trial is evaluating whether a small, specialized PET/CT scanner (micro-PET-CT) can help surgeons confirm in real time that all cancer has been removed during operations for head and neck cancer.
**You may be eligible if...**
- You are 18 or older with a malignant tumor in the mouth, throat, voice box, sinuses, or salivary glands
- Your cancer has not spread to distant organs (M0)
- You are scheduled for surgery and your cancer is considered operable
- You are covered under a social security plan (French social security required)
**You may NOT be eligible if...**
- You have severe liver failure (Child-Pugh C)
- You are under legal guardianship or protection
- You are pregnant or breastfeeding
- You have an allergy to the imaging tracer (18F-FDG)
- You have uncontrolled diabetes
- You have moderate to severe kidney disease
- You are unable to understand or comply with study requirements
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DEVICEmicro PET/CT
PET/T of the speciment after surgery
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07285564
Related Trials
Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell Carcinoma
NCT074450481 location
Role of the Immune System in Preventing Laryngeal Cancer
NCT075083191 location
Impact of Early Response to First-line Anti-PD-1 Monotherapy in Patients With Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma, Assessed by 18F-FDG PET/CT
NCT074487271 location
A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1
NCT072921685 locations
Improving Dental Care for Patients With Head and Neck Tumors
NCT073283471 location